Qualität

Eigenschaften

Molare Masse 404.24

CAS RN [84226-06-2]

Reinheit ≥ 95 %

• Dark yellow oil

Zertifikate

CoA: appearance, ¹H NMR spectrum

Literatur

Kung H.F. et al. Dopamine D-2 receptor Imaging Radiopharmaceuticals: Synthesis, Radiolabeling and in Vitro binding of R(+)- and S(–)-3-iodo-2-hydroxy-6-methoxy-N-[(1-ethyl-2-pyrrolidinyl)methyl]benzamide. J. Med. Chem. 1988, 31, 1039–1043.

Cordes M. et al. Initial experience with SPECT examinations using [¹²³I]IBZM as a D2-dopamine receptor antagonist in Parkinson's disease. Eur. J. Radiol. 1991, 12, 182.

Innis R.B. et al. Amphetamine-stimulated dopamine release competes in vivo for [¹²³I]IBZM binding to the D2receptor in nonhuman primates. Synapse 1992, 10, 177.

Ichise M. et al. Iodine-123-IBZM dopamine D2receptor and technetium -99 m-HMPAO brain perfusion SPECT in the evaluation of patients with and subjects at risk for Huntington's disease J. Nucl. Med. 1993, 34, 1274.